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Periapical bone response to bacterial 
lipopolysaccharide is shifted upon 
cyclooxygenase blockage
Objectives: Infection, inflammation and bone resorption are closely 
related events in apical periodontitis development. Therefore, we sought 
to investigate the role of cyclooxygenase (COX) in osteoclastogenesis 
and bone metabolism signaling in periapical bone tissue after bacterial 
lipopolysaccharide (LPS) inoculation into root canals. Methodology: Seventy 
two C57BL/6 mice had the root canals of the first molars inoculated with 
a solution containing LPS from E. coli (1.0 mg/mL) and received selective 
(celecoxib) or non-selective (indomethacin) COX-2 inhibitor. After 7, 14, 
21 and 28 days the animals were euthanized and the tissues removed for 
total RNA extraction. Evaluation of gene expression was performed by qRT-
PCR. Statistical analysis was performed using analysis of variance (ANOVA) 
followed by post-tests (α=0.05). Results: LPS induced expression of mRNA 
for COX-2 (Ptgs2) and PGE2 receptors (Ptger1, Ptger3 and Ptger4), indicating 
that cyclooxygenase is involved in periapical response to LPS. A signaling that 
favours bone resorption was observed because Tnfsf11 (RANKL), Vegfa, Ctsk, 
Mmp9, Cd36, Icam, Vcam1, Nfkb1 and Sox9 were upregulated in response 
to LPS. Indomethacin and celecoxib differentially modulated expression of 
osteoclastogenic and other bone metabolism genes: celecoxib downregulated 
Igf1r, Ctsk, Mmp9, Cd36, Icam1, Nfkb1, Smad3, Sox9, Csf3, Vcam1 and Itga3 
whereas indomethacin inhibited Tgfbr1, Igf1r, Ctsk, Mmp9, Sox9, Cd36 and 
Icam1. Conclusions: We demonstrated that gene expression for COX-2 and 
PGE2 receptors was upregulated after LPS inoculation into the root canals. 
Additionally, early administration of indomethacin and celecoxib (NSAIDs) 
inhibited osteoclastogenic signaling. The relevance of the cyclooxygenase 
pathway in apical periodontitis was shown by a wide modulation in the 
expression of genes involved in both bone catabolism and anabolism.
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Introduction
Apical periodontitis is a localized immune response 
towards microorganisms present within the tooth 
root canal.1 Untreated inflammatory response in the 
periapical region leads to resorption of bone and dental 
tissue, culminating in the loss of the tooth.2,3 Gram-
negative bacteria, a major component of infected 
root canals, present lipopolysaccharide (LPS) as a 
component of the outer cellular wall, which is a potent 
stimulator of immune response, released mainly during 
bacterial death.4-6 In the periapical area, LPS induces 
osteoclastogenic signaling, which culminates in bone 
resorption.7,8
Biochemical mediators are released locally to 
stimulate immune response during inflammatory 
events. Structural changes in arachidonic acid 
chains caused by cyclooxygenases (COX) lead to 
the synthesis of prostaglandins and thromboxanes.9 
Cyclooxygenases are found in 2 isoforms, named COX-
1 and COX-2. COX-1 is produced and constitutively 
expressed on most tissues, whereas COX-2 is produced 
in response to inflammatory stimuli and stimulates the 
production of prostaglandins involved in inflammatory 
reaction and is not usually found in most tissues under 
physiological conditions.10,11 Bacterial LPS induces 
prostaglandin E2 (PGE2) by macrophages,12 which 
activates protein-G coupled with EP1, EP2, EP3 and 
EP4 receptors in order to promote distinct cellular 
response.13,14
Cyclooxygenases are inhibited by nonsteroidal 
anti-inflammatory drugs (NSAIDs), a heterogeneous 
group of medications, which results in a reduction in 
the synthesis of prostaglandins, thus controlling pain, 
inflammation, and fever. NSAIDs might inhibit COX-1 or 
COX-2.10 selectively or specifically. The administration 
of a COX non-selective inhibitor (indomethacin) during 
the development of apical periodontitis resulted 
in lower intensity of the inflammatory infiltrate 
concomitant with less bone resorption,15,16 although 
the signaling involved in bone loss was not further 
investigated. Interestingly, in vitro, a COX-2 selective 
inhibitor (celecoxib) impaired osteoclast formation, 
suggesting prostaglandins have a role in bone 
resorption.11,17 We have previously demonstrated that 
the 5-lipoxygenase inhibitor is able to regulate RANK/
RANKL/OPG in apical periodontitis;18 however, studies 
showing the effects of a COX-2 selective inhibitor and 
a non-selective COX-2 inhibitor on the regulation of 
RANK, RANKL, OPG and other genes involved in bone 
metabolism following root canal inoculation with LPS 
has not been reported. Because infection, inflammation 
and bone resorption are closely related events in 
apical periodontitis development, we hypothesized 
that blockage in the cyclooxygenase pathway would 
change the signaling involved in periapical bone 
response to bacterial lipopolysaccharide. For that 
reason, we used non-selective (indomethacin) and 
selective (celecoxib) cyclooxygenase inhibitors, mostly 
because indomethacin treatment impairs bone loss15 
but presents several side effects,10 whereas celecoxib 
treatment is more specific but its effects on apical 
periodontitis development are not known.
Therefore, the aim of this study was to evaluate 
the expression of messenger mRNA of COX-2, PGE2 
receptors, and osteoclastogenesis mediators (RANK, 
RANKL and OPG) in bone tissue after LPS inoculation 
into the root canals, and the effect of indomethacin 
and celecoxib in the blockage of the inflammatory 
response induced via COX expression. Moreover, we 
investigated the effects of COX inhibition in a wide 
range of genes involved in bone metabolism.
Methodology
Animals
Seventy two C57BL/6 6-week-old male mice 
(Mus musculus) were used for experimentation after 
IRB approval (#10.1.1618.53.0). Animals were 
anesthetized i.m. with 10% ketamine hydrochloride 
(150 mg/kg; National Pharmaceutical Chemistry Union 
Agener S/A, Embu-Guaçu, SP, Brazil) and xylazine (7.5 
mg/kg; Dopaser, Labs Calier S/A, Barcelona, Spain) 
for operative procedures. Anesthesia was sustained 
throughout the experimental period.18
Operative procedures
The animals were placed in a surgical table with a 
device for mandibular retraction. The right upper and 
lower first molars of each animal were used for LPS 
inoculation into the root canals.
Occlusal root canal accesses were gained with 
1011 spherical diamond burs (KG Sorensen Ind. Com. 
Ltda., Barueri, SP, Brazil), root canals were located 
with a #06 K-file (Les Fils d’ Auguste Maillefer S/A, 
Ballaigues, Switzerland), and the radicular pulp tissue 
was removed.18 Then, 10 µL of  LPS suspension (1.0 
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mg/mL) from E. coli 0127: B8 (L3129; Sigma-Aldrich 
Corp., St. Louis, MO, USA) were inoculated within 
root canals of each tooth by means of an automatic 
micropipette. The teeth were sealed with conventional 
glass ionomer cement (S.S. White Dental Articles Ltda, 
Rio de Janeiro, RJ, Brazil), mixed in accordance with 
the manufacturer’s instructions. Tissues were collected 
7, 14, 21 and 28 days after LPS inoculation into the 
root canals (n=6 teeth per group).
Indomethacin and celecoxib treatment
Indomethacin (Cayman Chemical, Ann Arbor, MI, 
USA) solution was prepared in saline with 5% NaHCO3 
and was given i.p. (5 mg/kg), one hour prior to LPS 
inoculation into the root canals, and daily throughout 
the experimental period. Celecoxib (Pfizer Inc., La 
Jolla, CA, USA) was prepared in ethanol and saline, 
being provided gavage (15 mg/kg) one hour prior to 
LPS inoculation into the root canals as well as daily 
throughout the experimental period. Healthy teeth 
from animals that did not receive medication were 
used as control.
Total RNA extraction
Animals were euthanized by i.m. anaesthetic 
overdose, using 10% ketamine (300 mg/kg) and 
xylazine (30 mg/kg). Afterwards, the tissues containing 
bone and tooth were collected and frozen immediately. 
A pool of three teeth was used for RNA extraction as 
previously described.18 RNA was extracted from tissues 
using the RNeasy Mini kit (RNeasy® Mini, Qiagen Inc., 
Valencia, CA, USA) and the samples were treated 
with DNAse I (RNase-Free DNase Set; Qiagen Inc.), 
according to manufacturer protocol. RNA integrity 
was analyzed using 1% agarose electrophoresis and 
quantity was estimated in NanoDrop 1000 (Thermo 
Fisher Scientific Inc., Wilmington, DE, USA) at 230, 
260 and 280 nm wavelengths.
Quantitative reverse transcriptase-polymerase 
chain reaction (qRT-PCR)
Complimentary DNA (cDNA) was synthesized from 
1000 ng of total RNA using random primers (High 
Quality cDNA Reverse Transcriptase Kits, Applied 
Biosystems, Foster City, CA, USA). Aliquots of 2 µl 
of the total cDNA were amplified by qRT-PCR using 
the primers for Ptgs2 (COX-2; Mm00478374), Ptger1 
(EP1; Mm00443098), Ptger2 (EP2; Mm00436051), 
Ptger3  (EP3; Mm01316856), Ptger4  (EP4; 
Mm00436053), Tnfrsf11a (RANK; Mm00437135), 
Tnfsf11 (RANKL; Mm00441906) and Tnfrsf11b (OPG; 
Mm01205928) (TaqMan® Gene Expression Assay, 
Applied Biosystems) in an Eppendorf Mastercycler® 
ep Realplex (Eppendorf AG, Hamburg, Germany). 
Gapdh (GAPDH; Mm99999915) was used as reference 
gene. Amplification was done under the following 
conditions: denaturation at 95°C for 10 min; followed 
by 40 cycles of 95°C, 15 s and 60°C, 1 min. Reactions 
were performed in duplicate and relative quantification 
was performed using the ΔΔCt Method. Relative 
expression was compared using one-way ANOVA 
followed by Dunnett’s test or two-way ANOVA followed 
by Bonferroni test (α=0.05).
qRT-PCR array
Global evaluation of genes involved in bone 
metabolism was performed using a commercially 
available qRT-PCR PCR Array (Osteogenesis RT² 
Profiler PCR Array, PAMM-026; Qiagen Inc.). cDNA 
was synthesized from 200 ng of total RNA using 
the RT2 First Strand kit (Qiagen Inc.) to evaluate 84 
genes involved in osteogenesis. qRT-PCR amplification 
was performed in an Eppendorf Mastercycler® ep 
Realplex (Eppendorf AG) using SybrGreen. Gusb, Hprt, 
Hsp90ab1, Actb and Gapdh were used as reference 
genes. Amplification was done under the following 
conditions: denaturation at 95°C for 10 min; followed 
by 40 cycles of 95°C for 15 s and 60°C for 1 min. 
Dissociation curve was evaluated in order to determine 
the specificity of the primers, considering the melting 
temperature of the amplicon under the following 
conditions: temperature increase to 95°C for 15 s, 
followed by temperature decrease to 60°C for 15 s, 
gradually increasing the temperature to 95°C for 20 
min and maintaining it at 95°C for 15 min. Relative 
quantification was performed using the ΔΔCt Method 
using healthy teeth as calibrators. Statistical analysis 
was performed using one-way ANOVA followed by 
Dunnett’s test (α=0.05).
Results
LPS induces expression of mRNA for COX-2, PGE2 
receptors and regulators of osteoclastogenesis
Inoculation of LPS into the root canals induced 
the expression of Ptgs2, mostly at 14 days following 
inoculation. After 21 days, Ptgs2 expression decreased, 
although it remained higher than healthy teeth (Figure 
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1A). Because the peak of COX-2 expression was 
observed at 14 days, we investigated the expression 
of PGE2 receptors in this period. We observed that LPS 
induced expression of Ptger1, Ptger3 and Ptger4, but 
exerted no influence on Ptgs2, which remained similar 
to healthy teeth (Figure 1B).
Tnfsf11 expression, which encodes RANKL, 
increased at 7 and 21 days upon LPS stimulation 
but did not change at 14 and 28 days. Tnfrsf11b 
expression, which encodes OPG, increased at 7 days, 
but it was no different from healthy teeth after that. 
Tnfrsf11a expression, which encodes RANK, remained 
unchanged at all experimental periods (Figure 2).
Figure 1- Ptgs2 relative gene expression at 7, 14, 21 and 28 days following LPS inoculation into the root canals of mice (A) PGE2 receptors 
(Ptger1, Ptger2, Ptger3, Ptger4) were evaluated at 14 days following LPS inoculation into the root canals of mice (B) * p<0.05 compared 
to healthy teeth (control)
Figure 2- Relative expression of Tnfsf11, Tnfrsf11b and Tnfrsf11a which respectively encodes RANKL (A), OPG (B) and RANK (C), 7, 
14, 21 and 28 days following LPS inoculation into the root canals of mice. After LPS inoculation, selective (celocoxib) or non-selective 
(indomethacin) COX-2 inhibitors were administered daily to the animals. * p<0.05 compared to healthy teeth; # p<0.05 compared to LPS 
inoculation alone
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Indomethacin and celecoxib differentially 
modulate expression of osteoclastogenic genes
Administration of indomethacin, a COX-2 non-
selective inhibitor, inhibited expression of RANK gene 
(Tnfrsf11a) at 7 and 14 days and exerted no effect at 
21 days but stimulated expression at 28 days. RANKL 
gene (Tnfsf11) expression was inhibited at 7 and 21 
days but increased at 14 and 28 days. The expression 
OPG gene (Tnfrsf11b) was stimulated at 14 and 21 
days but did not change at 7 and 28 days (Figure 2).
On the other hand, administration of celecoxib, a 
COX-2 selective inhibitor, reduced the expression of 
RANK gene (Tnfrsf11a) at 7 days but increased at 14 
and 28 days, with no change at 21 days compared 
to the LPS inoculation alone. RANKL gene (Tnfsf11) 
expression decreased at 7 and 21 days following 
treatment but increased at 14 and 28 days. The 
expression OPG gene (Tnfrsf11b) was not modulated 
by celecoxib treatment (Figure 2).
In vivo LPS induces expression of genes 
involved in bone metabolism that are regulated 
by indomethacin and celecoxib
Because Ptgs2 expression highly increased in 
early response to LPS inoculation into the root canal 
(14 days), a wide selection of genes involved in 
bone metabolism was investigated upon treatment 
with a selective (celecoxib) or non-selective COX-2 
(indomethacin) inhibitor.
At 14 days, LPS inoculation into the root canals 
increased mRNA expression of Tgfbr1, Igf1r, Vegfa, 
Ctsk, Mmp9, Cd36, Icam, Vcam1, Nfkb1, Smad 3 
and Sox9. Celecoxib administration downregulated 
Igf1r, Ctsk, Mmp9, Cd36, Icam1, Nfkb1, Smad 3, 
Sox9, Csf3, Vcam1 and Itga3 but upregulated Tgfbr1, 
Vegfa, Col10a1, Comp and Itgam. Indomethacin 
administration inhibited Tgfbr1, Igf1r, Ctsk, Mmp9, 
Sox9, Cd36, Icam1, and stimulated Bmp3, Vegfa, 
Csf3, Col2a1, Col6a1, Col7a1, Itga3 and Smad3 
(Figure 3).
Bmp5, Ambn, Ahsg, Enam and Tnf were not 
detected in any group. Alpl, Anxa5, Bgn, Bmp1, 
Bmp2, Bmp6, Bmpr1a, Cdh11, Col1a1, Col1a2, 
Col3a1, Col4a1, Col4a2, Col5a1, Col6a2, Col11a1, 
Col12a1, Col14a1, Dmp1, Egf, Fgf1, Fgf2, Fgfr1, 
Fgfr2, Fn1, Igf1, Itga1, Itga2b, Itga5, Itgb1, Mmp2, 
Mmp8, Mmp10, Msx1, Phex, Pdgfa, Runx2, Scarb1, 
Smad1, Smad2, Smad4, Serpinh1, Sost, Tfip11, Tgfb1, 
Tgfb3, Tgfbr2, Tuft1, Twist1, Vdr and Vegfb were not 
modulated upon LPS stimulation or treatment with 
indomethacin or celecoxib (Table 1). Bmp4, Bmpr1b, 
Csf2, Fgf3, Flt1, Gdf10, Tgfb2 and Tgfbr3 were not 
Figure 3- Relative expression of genes that encode growth factors (A), extracellular matrix (ECM) proteins (B), osteogenic transcription 
factors (C) and cellular adhesion molecules (D) 14 days following LPS inoculation into the root canals of mice, with or without selective 
(celocoxib) or non-selective (indomethacin) COX-2 inhibitors administered daily. * p<0.05 compared to healthy teeth; # p<0.05 compared 
to LPS inoculation alone; & p<0.05 compared to LPS + celocoxib (15 mg/kg)
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detected in either positive or negative controls, i.e. 
LPS inoculation alone or health teeth, respectively. 
Therefore, further comparison between groups 
regarding the expression of the aforementioned genes 
could not be carried out.
Symbol Gene expression p value
Healthy teeth LPS  
(1.0 mg/mL)
LPS + celecoxib  
(15 mg/kg)
LPS + indomethacin  
(5 mg/kg)
Alpl 1.0 (± 0.12) 0.36 (± 1.98) 0.11 (± 0.13) 0.40 (± 0.12) 0.98
Anxa5 1.0 (± 0.10) 1.06 (± 1.62) 0.49 (± 0.15) 1.54 (± 0.09) 0.83
Bgn 1.0 (± 0.12) 1.32 (± 0.68) nd 1.66 (± 0.11) 0.38
Bmp1 1.0 (± 0.10) 1.7 (± 0.91) nd 1.83 (± 0.10) 0.37
Bmp2 1.0 (± 0.12) 0.27 (± 2.61) nd 0.24 (± 0.19) 0.85
Bmp6 1.0 (± 0.15) nd nd nd -
Bmpr1a 1.0 (± 0.10) 0.79 (± 0.68) 0.96 (± 0.27) 0.49 (± 0.10) 0.56
Cdh11 1.0 (± 0.10) 1.19 (± 0.66) 0.18 (± 0.15) 0.41 (± 0.10) 0.11
Col1a1 1.0 (± 0.09) 1.59 (± 0.96) 0.28 (± 0.14) 0.92 (± 0.09) 0.20
Col1a2 1.0 (± 0.10) 1.65 (± 0.77) 0.30 (± 0.27) 0.54 (± 0.11) 0.10
Col3a1 1.0 (± 0.11) 0.76 (± 0.75) 0.03 (± 0.14) 0.27 (± 0.09) 0.66
Col4a1 1.0 (± 0.13) 1.44 (± 0.63) nd 2.75 (± 0.10) 0.10
Col4a2 1.0 (± 0.11) 1.0 (± 0.68) 0.39 (± 0.36) 1.97 (± 0.10) 0.06
Col5a1 1.0 (± 0.11) 0.71 (± 0.63) nd 0.66 (± 0.09) 0.65
Col6a2 1.0 (± 0.11) 1.02 (± 0.63) 0.32 (± 0.17) 0.37 (± 0.09) 0.18
Col11a1 1.0 (± 0.13) 0.92 (± 0.70) 0.08 (± 0.13) 0.19 (± 0.16) 0.13
Col12a1 1.0 (± 0.10) 0.68 (± 0.63) 0.18 (± 0.17) 0.13 (± 0.09) 0.15
Col14a1 1.0 (± 0.10) 0.26 (± 1.18) 0.13 (± 0.13) 0.04 (± 0.70) 0.45
Dmp1 1.0 (± 0.11) 1.31 (± 0.92) nd 0.91 (± 0.11) 0.75
Egf 1.0 (± 0.11) 1.41 (± 1.79) 2.73 (± 0.28) 1.39 (± 0.09) 0.36
Fgf1 1.0 (± 0.10) 0.88 (± 0.63) 0.67 (± 0.18) 1.71 (± 0.10) 0.11
Fgf2 1.0 (± 0.10) nd 0.74 (± 0.19) 0.60 (± 0.11) 0.13
Fgfr1 1.0 (± 0.07) nd nd nd -
Fgfr2 1.0 (± 0.10) 0.36 (± 0.73) 0.20 (± 0.72) 1.46 (± 0.11) 0.19
Fn1 1.0 (± 0.11) 1.34 (± 1.06) 1.15 (± 0.16) 0.97 (± 0.10) 0.89
Igf1 1.0 (± 0.09) 0.40 (± 0.64) 0.08 (± 0.14) 0.60 (± 0.09) 0.18
Itga1 1.0 (± 0.15) nd nd 0.67 (± 0.14) 0.15
Itga2b 1.0 (± 0.11) 0.50 (± 0.64) 0.80 (± 0.43) 0.73 (± 0.11) 0.67
Itga5 1.0 (± 0.12) 0.33 (± 0.71) 0.75 (± 0.19) 0.29 (± 0.11) 0.31
Itgb1 1.0 (± 0.11) 1.02 (± 1.32) 0.55 (± 0.58) 1.17 (± 0.10) 0.84
Mmp2 1.0 (± 0.10) 1.11 (± 0.94) nd 0.92 (± 0.90) 0.96
Mmp8 1.0 (± 0.10) 1.83 (± 1.73) nd 0.60 (± 0.10) 0.53
Mmp10 1.0 (± 0.11) 0.67 (± 0.77) nd 0.76 (± 0.14) 0.77
Msx1 1.0 (± 0.10) 0.68 (± 0.84) nd 1.83 (± 0.09) 0.19
Phex 1.0 (± 0.10) 0.97 (± 0.68) 0.69 (± 0.19) 0.04 (± 0.18) 0.16
Pdgfa 1.0 (± 0.12) 1.53 (± 1.22) 0.91 (± 0.13) 2.22 (± 0.10) 0.26
Runx2 1.0 (± 0.10) 1.56 (± 0.80) nd 1.92 (± 0.06) 0.28
Scarb1 1.0 (± 0.10) nd nd 1.20 (± 0.09) 0.16
Smad1 1.0 (± 0.11) 0.92 (± 0.64) 1.39 (± 0.41) 0.39 (± 0.10) 0.22
Smad2 1.0 (± 0.11) 0.71 (± 1.75) nd 1.16 (± 0.10) 0.90
Smad4 1.0 (± 0.12) 1.04 (± 0.99) 1.5 (± 0.17) 0.37 (± 0.10) 0.31
Serpinh1 1.0 (± 0.11) 0.87 (± 0.63) 0.69 (± 0.32) 0.35 (± 0.10) 0.41
Sost 1.0 (± 0.11) 0.60 (± 0.69) 0.89 (± 0.20) 0.83 (± 0.10) 0.75
 Tfip11 1.0 (± 0.11) 1.4 (± 0.64) 1.69 (± 0.14) 1.49 (± 0.13) 0.34
Tgfb1 1.0 (± 0.12) 0.87 (± 0.63) nd 1.16 (± 0.12) 0.75
Tgfb3 1.0 (± 0.11) 0.93 (± 0.63) nd 0.37 (± 0.14) 0.32
Tgfbr2 1.0 (± 0.10) 0.5 (± 1.00) 3.58 (± 1.62) 0.42 (± 0.10) 0.07
Tuft1 1.0 (± 0.12) 0.84 (± 1.04) 1.08 (± 0.27) 2.08 (± 0.11) 0.23
Twist1 1.0 (± 0.11) 0.55 (± 1.01) 0.52 (± 0.14) 0.89 (± 0.10) 0.73
Vdr 1.0 (± 0.12) 0.82 (± 1.09) 0.29 (± 0.21) 0.97 (± 0.10) 0.60
Vegfb 1.0 (± 0.10) nd nd 0.68 (± 0.12) 0.10
nd - not 
detected
Table 1- Gene expression not modulated during apical periodontitis development or upon treatment with indomethacin or celocoxib 
inhibitors for 14 days following root canal with LPS inoculation. Values depict mean (± standard deviation)
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Discussion
We demonstrated that LPS inoculation into the root 
canals stimulated gene expression, encoding the COX-
2 enzyme involved in the metabolism of arachidonic 
acid (Ptgs2) and PGE2 receptors, concomitantly to the 
expression modulation of osteoclastogenesis markers. 
The administration of a selective celecoxib) or non-
selective (indomethacin) COX-2 inhibitor differentially 
regulated genes involved in bone metabolism.
The involvement of prostaglandins in apical 
periodontitis development has been previously 
demonstrated. Significantly higher concentrations of 
PGE2 were found in acute lesions when compared to 
chronic injuries,16,19 indicating a role for PGs in the 
pathogenesis of apical periodontitis. We observed 
a high Ptgs2 gene expression at 14 days after LPS 
inoculation into root canals with subsequent decline, 
corroborating previous studies showing increased 
synthesis of prostaglandins in initial periods of 
response to contamination of root canals.20,21 Increased 
expression of Ptger1, Ptger3 and Ptger4 upon LPS 
inoculation into the root canals indicate that PGE2 
might have been generated through arachidonic acid 
metabolism by COX-2 in order to signal through EP1, 
EP3 and EP4 receptors.13,14,22 Indeed, EP4 signaling 
under LPS stimulation induces osteoclast formation 
and periodontal bone destruction.16
COX2 derivatives are involved in periapical 
inflammatory response and daily administration of 
indomethacin results in a significantly reduced level 
of periapical bone resorption,15 although the role 
of COX metabolites in the regulation of bone loss 
in apical periodontitis is not well known. Here, we 
demonstrated that administration of indomethacin 
inhibited RANKL expression and increased OPG 
expression in early response to LPS, shedding light 
on a possible mechanism that resulted in the reduced 
bone resorption previously observed. In agreement, 
a COX-2 selective inhibitor (celecoxib) acts directly 
on circulating osteoclast precursors in order to inhibit 
osteoclast formation without exerting cytotoxic effect 
in vitro.11,23 Previous studies have shown that early 
intervention in the COX-2 pathway modulates the 
gene expression of OPG, RANKL, RANK and other 
genes involved in the bone metabolism of induced 
arthritis in mice.17
In this study, we investigated the expression of 
genes regulating bone anabolism and catabolism 
in response to LPS. Several growth factors, cell 
differentiation, cellular adhesion, molecules and 
transcription factors were expressed 14 days in the 
apical periodontitis area upon LPS inoculation: Tgfbr1, 
Igl1r, Vegfa, Ctsk, Mmp9, Nfkb1, Smad3, Sox9, Cd36, 
Icam1 and Vcam1. Vascular endothelial growth factors 
(Vegf) and their receptors control vasculogenesis 
and are also involved in bone resorption in apical 
periodontitis.3,24 In this study, we observed an 
increase in Vegfa upon LPS inoculation, with enhanced 
expression after administration of celecoxib and 
indomethacin. Apart from vasculogenesis, it has 
been speculated that immune cells communicate 
with each other and with endothelial cells in human 
apical periodontitis through VEGF since clustered 
ELA2, CD68, CD3 and CD19 immune cells are VEGFA, 
VEGFR-2, VEGFR-3 and VEGFD positive.3
Cell adhesion molecules such as Vcam1 and 
Icam1 play a role in leukocyte migration to the site 
of infection. Icam1 deficiency results in compromised 
immune response reflected by enhanced periapical 
inflammation and bone resorption.25 In this study, 
we observed that indomethacin inhibited Icam1 
expression and celecoxib inhibited both Icam1 and 
Vcam1. 
Osteoclastogenesis markers Mmp9 and Ctsk were 
stimulated in LPS inoculation but were inhibited by 
both celecoxib and indomethacin. MMP-9 is important 
for initiating the osteoclastic resorption process 
by removing the collagenous layer from the bone 
surface prior to mineral loss.26 In apical periodontitis, 
expression and activity of MMP-9 was found to be 
significantly higher than that in normal periodontal 
ligament tissue.27,28 Although it has been reported 
that MMP-9 knockout mice develop larger apical 
periodontitis than wild mice,29 those findings should 
be carefully interpreted since several MMPs might 
exert compensatory effect, colaborating with enhanced 
bone loss. Another protease, cathepsin K, is highly 
expressed by osteoclasts to promote degradation 
type I of collagen, resulting in bone destruction.30 
Administration of cathepsin K inhibitor effectively 
downregulated apical periodontitis development and 
synthesis of proinflammatory cytokines.31
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Conclusions
We demonstrated that gene expression for COX-2 
and PGE2 receptors is upregulated after LPS inoculation 
into the root canals and that early administration 
of indomethacin and celecoxib (NSAIDs) inhibits 
osteoclastogenic signaling. The relevance of the 
cyclooxygenase pathway in apical periodontitis is 
evidenced by a wide modulation in the expression of 
genes involved in both bone catabolism and anabolism. 
Our findings suggest that in vivo studies should be 
conducted to evaluate bone remodeling in apical 
periodontitis for a complimentary understanding of 
COX-related mechanisms in inflammatory periapical 
lesions. We envision that in future, local modulation of 
host response aimed at enhancing apical periodontitis 
resolution may supplement the traditional root canal 
treatment protocol.
Acknowledgments
This study was supported by the São Paulo Research 
Foundation (FAPESP 2010/17611-4 to FWGPS, 
2012/00045-1 to GGS and 2013/09595-7 to IBFP). 
This study was partially financed by the Coordination 
of Higher Education and Graduate Training - Brasil 




1- Márton IJ, Kiss C. Protective and destructive immune reactions 
in apical periodontitis. Oral Microbiol Immunol. 2000;15(3):139-50.
2- Graves DT, Oates T, Garlet GP. Review osteoimmunology and the 
host response in endodontic and periodontal lesions. J Oral Microbiol. 
2011;3:5304-18
3- Virtej A, Loes SS, Berggreen E, Bletsa A. Localization and signaling 
patterns of vascular endothelial growth factors and receptors in human 
periapical lesions. J Endod. 2013;39(5):605-11.
4- Graunaite I, Lodiene G, Maciulskiene V. Pathogenesis of apical 
periodontitis: a literature review. J Oral Maxillofac Res. 2012;2(4):e1.
5- Nair PNR. Pathogenesis of apical periodontitis and the causes of 
endodontic failures. Crit Rev Oral Biol Med. 2004;15(6):348-81.
6- Ahmed GM, El-Baz AA, Hashem AA, Shalaan AK. Expression levels of 
matrix metalloproteinase-9 and gram-negative bacteria in symptomatic 
and asymptomatic periapical lesions. J Endod. 2013;39(4):444-8.
7- Yang J, Su N, Du X, Chen L. Gene expression patterns in 
bone following lipopolysaccharide stimulation. Cell Mol Biol Lett. 
2014;19(4):611-22. 
8- Chuang FH, Tsai CC, Chen JH, Chen KK, Chen YK, Lin YC. Long-
term sequential receptor activator of NF-κB ligand (RANKL) and 
osteoprotegrin (OPG) expression in lipopolysaccharide-induced rat 
periapical lesions. J Oral Pathol Med. 2012;41(2):186-93.
9- Kovác J, Kovác D. Histopathology and etiopathogenesis of chronic 
apical periodontitis-periapical granuloma. Epidemiol Mikrobiol Imunol. 
2011;60(2):77-86.
10- Fitzpatrick FA. Cyclooxygenase enzymes: regulation and function. 
Curr Pharm Des. 2004;10(6):577-88.
11- Kawashima M, Fujikawa Y, Itonaga I, Takita C, Tsumura H. The 
effect of selective cyclooxygenase-2 inhibitor on human osteoclast 
precursors to influence osteoclastogenesis in vitro. Mod Rheumatol. 
2009;19:192-8.
12- Xiao L, Ornatowska M, Zhao G, Cao H, Yu H, Deng J, et al. 
Lipopolysaccharide induced expression of microsomal prostaglandin 
E synthase-1 mediates late-phase PGE2 production in bone marrow 
derived macrophages. Plos One. 2012;7(11):e50244.
13- Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: 
structures, properties, and functions. Physiol Rev 1999;70:1193-226.
14- Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 
2007;282(16):11613-7.
15- Oguntebi BR, Barker BF, Anderson DM, Sakumura J. The effect 
of indomethacin on experimental dental periapical lesions in rats. J 
Endod. 1989;15(3):117-21.
16- Oka H, Miyauchi M, Furusho H, Nishihara T, Takata T. Oral 
administration of prostaglandin E(2)-specific receptor 4 antagonist 
inhibits lipopolysaccharide-induced osteoclastogenesis in rat 
periodontal tissue. J Periodontol. 2012;83(4):506-13.
17- Naidu VG, Babu KR, Thwin MM, Satish RL, Kumar PV, 
Gopalakrishnakone P. RANKL targeted peptides inhibit osteoclastogenesis 
and attenuate adjuvant induced arthritis by inhibiting NF-kB activation 
and down regulating inflammatory cytokines. Chem Biol Interact. 
2013;203(2):467-79.
18- Paula-Silva FW, Petean IB, Silva LA, Faccioli LH. Dual role of 
5-lipoxygenase in bacterial-induced apical periodontitis. J Endod. 
2016;42(3):447-54.
19- Alptekin NO, Ari H, Haliloglu S, Alptekin T, Serpek B, Ataoglu T. The 
effect of endodontic therapy on periapical exudate neutrophil elastase 
and prostaglandin-E2 levels. J Endod. 2005;31(11):791-5.
20- Okiji T, Morita I, Sunada I, Murota S. Involvement of arachidonic 
acid metabolites in increases in vascular permeability in experimental 
dental pulpal inflammation in the rat. Arch Oral Biol. 1989;34(7):523-8. 
21- Ohkura N, Shigetani Y, Yoshiba N, Yoshiba K, Okiji T. Prostaglandin 
transporting protein-mediated prostaglandin E2 transport in 
lipopolysaccharide-inflamed rat dental pulp. J Endod. 2014;40(8):1112-
7.
22- Kawahara K, Hohjoh H, Inazumi T, Tsuchiya S, Sugimoto Y. 
Prostaglandin E2-induced inflammation: Relevance of prostaglandin E 
receptors. Biochim Biophys Acta. 2015;1851(4):414-21.
23- Igarashi K, Woo JT, Stern PH. Effects of a selective cyclooxygenase-2 
inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro. 
Biochem Pharmacol. 2002;63(3):523-32.
24- Bletsa A, Virtej A, Berggreen E. Vascular endothelial growth 
factors and receptors are up-regulated during development of apical 
periodontitis. J Endod. 2012;38(5):628-35.
25- De Rossi A, Rocha LB, Rossi MA. Interferon-gamma, interleukin-10, 
intercellular adhesion molecule-1, and chemokine receptor 5, but not 
interleukin-4, attenuate the development of periapical lesions. J Endod. 
2008;34(1):31-8.
26- Delaissé JM, Engsig MT, Everts V, del Carmen Ovejero M, Ferreras 
M, Lund L, et al. Proteinases in bone resorption: obvious and less 
obvious roles. Clin Chim Acta. 2000;291(2):223-34.
27- Paula-Silva FW, D'Silva NJ, Silva LA, Kapila YL. High matrix 
metalloproteinase activity is a hallmark of periapical granulomas. J 
Endod. 2009;35(9):1234-42. 
Periapical bone response to bacterial lipopolysaccharide is shifted upon cyclooxygenase blockage
J Appl Oral Sci. 2019;27:e201806419/9
28- Paula-Silva FW, Silva LA, Kapila YL. Matrix metalloproteinase 
expression in teeth with apical periodontitis is differentially modulated 
by the modality of root canal treatment. J Endod. 2010;36(2):231-7.
29- Wan C, Yuan G, Yang J, Sun Q, Zhang L, Zhang J, et al. MMP-
9 deficiency increased the size of experimentally induced apical 
periodontitis. J Endod. 2014;40(5):658-64.
30- Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, 
Rommerskirch W, et al. Impaired osteoclastic bone resorption leads 
to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S 
A. 1998;95(23):13453-8.
31- Suzuki N, Takimoto K, Kawashima N. Cathepsin K inhibitor regulates 
inflammation and bone destruction in experimentally induced rat 
periapical lesions. J Endod. 2015;41(9):1474-9.
RIBEIRO-SANTOS FR, SILVA GG, PETEAN IBF, ARNEZ MFM, SILVA LAB, FACCIOLI LH, PAULA-SILVA FWG
